Studiefonds Cardiologie

Study by W. Mullens: Heart failure (HF) is prevalent with an increasing incidence due to ageing. Prognosis remains poor with a reduced quality of life. Novel quadruple HF therapy has proven to reduce morbidity and mortality in HF with a reduced ejection fraction. However, drug implementation is often hampered, especially in patients with chronic kidney disease who may have the largest benefit due to a higher event rate. This trial evaluates the benefit of a protocol-driven initiation and up-titration of therapy.